U.S. markets close in 2 hours 57 minutes
  • S&P 500

    3,892.91
    +81.76 (+2.15%)
     
  • Dow 30

    31,493.70
    +561.33 (+1.81%)
     
  • Nasdaq

    13,511.84
    +319.50 (+2.42%)
     
  • Russell 2000

    2,267.39
    +66.33 (+3.01%)
     
  • Crude Oil

    61.03
    -0.47 (-0.76%)
     
  • Gold

    1,724.90
    -3.90 (-0.23%)
     
  • Silver

    26.75
    +0.31 (+1.15%)
     
  • EUR/USD

    1.2042
    -0.0045 (-0.37%)
     
  • 10-Yr Bond

    1.4500
    -0.0100 (-0.68%)
     
  • GBP/USD

    1.3914
    -0.0008 (-0.06%)
     
  • USD/JPY

    106.7890
    +0.2870 (+0.27%)
     
  • BTC-USD

    48,641.92
    +4,955.65 (+11.34%)
     
  • CMC Crypto 200

    971.97
    +43.74 (+4.71%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Will Kiniksa Pharmaceuticals Continue to Surge Higher?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

As of late, it has definitely been a great time to be an investor Kiniksa Pharmaceuticals, Ltd. KNSA.The stock has moved higher by 9.1% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider KNSA’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as KNSA has earned itself a Zacks Rank #1 (Strong Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Kiniksa Pharmaceuticals Ltd (KNSA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.